Atossa Therapeutics Inc. [NASDAQ: ATOS] loss -10.07% on the last trading session, reaching $2.50 price per share at the time. The company report on March 22, 2021 that Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, announced that it has entered into a securities purchase agreement with institutional investors to purchase $50.0 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and.75 warrants to purchase one share of common stock is $2.88.
Under the terms of the securities purchase agreement, the Company has agreed to sell 17,361,100 shares of the Company’s common stock and issue unregistered warrants to purchase up to an additional 13,020,825 shares of common stock in a concurrent private placement. The warrants have an exercise price of $2.88 per share, are exercisable immediately and will expire four and a half years following the date of issuance.
Atossa Therapeutics Inc. represents 71.57 million in outstanding shares, while the company has a total market value of $178.94 million with the latest information. ATOS stock price has been found in the range of $2.42 to $2.54.
If compared to the average trading volume of 24.59M shares, ATOS reached a trading volume of 20292028 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Atossa Therapeutics Inc. [ATOS]:
Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.
The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.38 The Price to Book ratio for the last quarter was 2.75, with the Price to Cash per share for the same quarter was set at 0.13.
Trading performance analysis for ATOS stock
Atossa Therapeutics Inc. [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.09. With this latest performance, ATOS shares dropped by -19.61% in over the last four-week period, additionally plugging by 2.46% over the last 6 months – not to mention a rise of 183.99% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 46.15, with the RSI for the last a single of trading hit 42.75, and the three-weeks RSI is set at 48.44 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 2.59, while it was recorded at 2.72 for the last single week of trading, and 2.49 for the last 200 days.
Atossa Therapeutics Inc. [ATOS]: A deeper dive into fundamental analysis
Return on Total Capital for ATOS is now -156.88, given the latest momentum, and Return on Invested Capital for the company is -156.92. Return on Equity for this stock declined to -157.00, with Return on Assets sitting at -131.50. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.38. Additionally, ATOS Total Debt to Total Capital is recorded at 0.38, with Total Debt to Total Assets ending up at 0.35. Long-Term Debt to Equity for the company is recorded at 0.09, with the Long-Term Debt to Total Capital now at 0.08.
Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,873,296 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.20.
Atossa Therapeutics Inc. [ATOS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Atossa Therapeutics Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 21.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ATOS.
An analysis of insider ownership at Atossa Therapeutics Inc. [ATOS]
There are presently around $4 million, or 5.40% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: VANGUARD GROUP INC with ownership of 518,109, which is approximately 148.022% of the company’s market cap and around 0.12% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 492,800 shares of the stock with an approximate value of $1.23 million in ATOS stocks shares; and VIRTU FINANCIAL LLC, currently with $0.69 million in ATOS stock with ownership of nearly New of the company’s market capitalization.
Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 9 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 1,080,042 shares. Additionally, 11 investors decreased positions by around 236,849 shares, while 6 investors held positions by with 247,382 shares. The mentioned changes placed institutional holdings at 1,564,273 shares, according to the latest SEC report filing. ATOS stock had 3 new institutional investments in for a total of 276,604 shares, while 8 institutional investors sold positions of 103,019 shares during the same period.